In the same publication, human FD biopsies from a Phase 1 clinical trial obtained before and after denosumab (anti-RANKL monoclonal antibody) treatment showed reduced expression of FAP after six months of denosumab therapy (Figure 2D). This evidence concerns the gene FAP and Fabry disease.